BRAF and neoplasm: Since 2017, the Food and Drug Administration (FDA) has approved six anticancer agents with a “histology-agnostic” indication: two immune checkpoint inhibitors (ICIs) for cancers with high tumor mutational burden (TMB) or mismatch repair deficiency/microsatellite instability (dMMR/MSI) [16,17,18] and four targeted therapies for tumors harboring a BRAF V600E mutation or a neurotrophic tyrosine receptor kinase (NTRK) gene fusion [19,20,21].